drughunter.com
7 minute read
Mar. 31, 2024

Patent Highlights: Synthetic Lethal MTA-Cooperative PRMT5 Inhibitors, TYK2 Degraders, Mutant p53 Reactivators, and More

Loading...

twitterlinkedinemail

Other articles you may be interested in

Key Clinical Compound Updates from August 2024

Here’s a rundown of August’s key clinical developments, including FDA approvals, potential upcoming approvals, notable trial readouts, new NDA submissions, and pipeline realignments.

July 2024 Molecule Roundup | 50 Molecules from July to Know

In this article, you'll find a curated selection of nearly 50 molecules from July that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

Key Clinical Compound Updates from September 2024

This summary of September's major clinical updates features FDA approvals, drug withdrawals, anticipated regulatory decisions, notable trial results, new NDA submissions, clinical trial setbacks, and the initiation of new clinical trials.

August 2024 Annotated Searchable Patent Table

We know keeping up with the latest developments in drug discovery can be a challenge, so we’ve simplified the process for you. We’ve reviewed thousands of newly published patent documents to bring you a curated list of over 200 key patents released in August 2024. Each entry comes with detailed commentary to help you navigate the content quickly and efficiently.

September 2024 Annotated Searchable Patent Table

Staying on top of the latest IP disclosures in drug discovery is no small feat, so we’ve made it easier for you! Our team sifted through thousands of recently published patents to compile a curated list of about 200 significant patent documents in the drug discovery space from September 2024. Each entry is accompanied by detailed annotations to help you quickly grasp the essentials.